Outlook Therapeutics receives FDA approval for Lytenava, the first ophthalmic bevacizumab for wet AMD
The U.S. Food and Drug Administration (FDA) has approved Outlook Therapeutics' (OTLK) Lytenava (bevacizumab-vikg) as a treatment for wet age-related macular degeneration (AMD). This marks the first FDA-approved ophthalmic formulation of bevacizumab, which is typically marketed by Roche (RHHBY) under the brand name Avastin. The drug will likely launch before the end of the year and is administered once a month. Lytenava's approval represents a significant milestone for Outlook Therapeutics, potentially expanding its market presence in ophthalmic treatments. Wet AMD affects millions globally and requires regular treatment to prevent vision loss. With this FDA clearance, Lytenava could offer an alternative therapy option with the potential to capture a share of the existing bevacizumab user base. The approval may also influence investor sentiment toward Outlook Therapeutics as it positions itself in a competitive therapeutic space.
Topics: biotech drug approval pharmaceuticals